deleobuvir
Small moleculeexperimental
Clinical trial activity
21 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT02182388)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Br)cn5)n(C)c4c3)CCC2)nc2ccc(/C=C/C(=O)O)cc21- Mol. weight
- 653.58 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2403318 ↗
- ChEMBLCHEMBL3137315 ↗
Also known as
- bi 207127
- bi 207127
- bi 207127
- bi 207127
- bi 207127 na
- bi 207127 na
- bi 207217
- deleobuvir
- deleobuvir
- deleobuvir
- deleobuvir sodium
- deleobuvir sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01983566 | Phase 1 | Nov 1, 2013 | Boehringer Ingelheim |
| NCT01941615 | Phase 1 | Nov 1, 2013 | Boehringer Ingelheim |
| NCT01957657 | Phase 1 | Oct 1, 2013 | Boehringer Ingelheim |
| NCT01965431 | Phase 1 | Oct 1, 2013 | Boehringer Ingelheim |
| NCT01859962 | Phase 2 | May 1, 2013 | Boehringer Ingelheim, Presidio Pharmaceuticals |
| NCT01858961 | Phase 3 | May 1, 2013 | Boehringer Ingelheim |
| NCT01830127 | Phase 2 | Apr 1, 2013 | Boehringer Ingelheim |
| NCT01732796 | Phase 3 | Dec 1, 2012 | Boehringer Ingelheim |
| NCT01728324 | Phase 3 | Nov 1, 2012 | Boehringer Ingelheim |
| NCT01737996 | Phase 1 | Nov 1, 2012 | Boehringer Ingelheim |
| NCT01605461 | Phase 1 | May 1, 2012 | Boehringer Ingelheim |
| NCT01525628 | Phase 1 | Apr 1, 2012 | Boehringer Ingelheim |
| NCT01535638 | Phase 1 | Feb 1, 2012 | Boehringer Ingelheim |
| NCT01528735 | Phase 2 | Feb 1, 2012 | Boehringer Ingelheim |
| NCT01347086 | Phase 1 | May 1, 2011 | Boehringer Ingelheim |
| NCT01132313 | Phase 2 | May 1, 2010 | Boehringer Ingelheim |
| NCT02182401 | Phase 1 | Jul 1, 2009 | Boehringer Ingelheim |
| NCT02182414 | Phase 1 | May 1, 2009 | Boehringer Ingelheim |
| NCT00905632 | Phase 1 | May 1, 2009 | Boehringer Ingelheim |
| NCT02176525 | Phase 1 | Dec 1, 2007 | Boehringer Ingelheim |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 21 | 20 | 3 | 2007 |
| Presidio Pharmaceuticals | For profit | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1